alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 740.17 Foaming detergent bath products. ( a ) For the purpose of this section, a foaming detergent bath product is any product intended to be added to a bath for the purpose of producing foam that contains a surface-active agent serving as a detergent or foaming ingredient.
( b ) The label of foaming detergent bath products within the meaning of paragraph (a) of this section, except for those products that are labeled as intended for use exclusively by adults, shall bear adequate directions for safe use and the following caution: *Caution*—Use only as directed. Excessive use or prolonged exposure may cause irritation to skin and urinary tract. Discontinue use if rash, redness, or itching occurs. Consult your physician if irritation persists. Keep out of reach of children.
( c ) In the case of products intended for use by children, the phrase “except under adult supervision” may be added at the end of the last sentence in the caution required by paragraph (b) of this section.
[51 FR 20475, June 5, 1986]
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Federal Maritime Commission
 Notice is hereby given that the following Ocean Transportation Intermediary licenses have been reissued by the Federal Maritime Commission pursuant to section 19 of the Shipping Act of 1984 (46 U.S.C. Chapter 409) and the regulations of the Commission pertaining to the licensing of Ocean Transportation Intermediaries, 46 CFR part 515. License No.
Name/address
Date reissued017678N
Four Link International, Inc., 146-27 167th Street, #100, Jamaica, NY 11434
January 2, 2010.018613N
Caribbean Cargo & Package Services, Inc., 147-46 176th Street, Jamaica, NY 11434
December 18, 2009.021418F
Asbun International Freight, Inc., 8140 NW. 74th Avenue, Suite 13 & 14, Medley, FL 33166
January 4, 2010.( print page 9603)021476F
Norma's Cargo Solutions LLC, 5665 SW. 8th Street, Miami, FL 33134
January 21, 2010.
 Sandra L. Kusumoto, Director, Bureau of Certification and Licensing.


[FR Doc. 2010-4418 Filed 3-2-10; 8:45 am] BILLING CODE 6730-01-P
§ 530.12 Labeling. Any human or animal drug prescribed and dispensed for extralabel use by a veterinarian or dispensed by a pharmacist on the order of a veterinarian shall bear or be accompanied by labeling information adequate to assure the safe and proper use of the product. Such information shall include the following: ( a ) The name and address of the prescribing veterinarian. If the drug is dispensed by a pharmacy on the order of a veterinarian, the labeling shall include the name of the prescribing veterinarian and the name and address of the dispensing pharmacy, and may include the address of the prescribing veterinarian;
( b ) The established name of the drug or, if formulated from more than one active ingredient, the established name of each ingredient;
( c ) Any directions for use specified by the veterinarian, including the class/species or identification of the animal or herd, flock, pen, lot, or other group of animals being treated, in which the drug is intended to be used; the dosage, frequency, and route of administration; and the duration of therapy;
( d ) Any cautionary statements; and
( e ) The veterinarian's specified withdrawal, withholding, or discard time for meat, milk, eggs, or any other food which might be derived from the treated animal or animals.
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3280 Castor oil, hydrogenated.

Hydrogenated castor oil may be safely used in the manufacture of articles or components of articles intended for use in contact with food subject to the provisions of this section.

(a) The quantity used shall not exceed the amount reasonably required to accomplish the intended technical effect.

(b) The additive is used as follows:

| Use | Limitations |
| --- | --- |
| 1. As a lubricant for vinyl chloride polymers used in the manufacture of articles or components of articles authorized for food-contact use | For use only at levels not to exceed 4 pct by weight of vinyl chloride polymers. |
| 2. As a component of cellophane | Complying with § 177.1200 of this chapter. |
| 3. As a component of resinous and polymeric coatings | Complying with § 175.300 of this chapter. |
| 4. As a component of paper and paperboard in contact with aqueous and fatty food | Complying with § 176.170 of this chapter. |
| 5. As a component of closures with sealing gaskets for food containers | Complying with § 177.1210 of this chapter. |
| 6. As a component of cross-linked polyester resins | Complying with § 177.2420 of this chapter. |
| 7. As a component of olefin polymers complying with § 177.1520 of this chapter | For use only at levels not to exceed 2 percent by weight of the polymer. |

[42 FR 14609, Mar. 15, 1977, as amended at 55 FR 8914, Mar. 9, 1990]
§ 74.2602a Ext. D&C Violet No. 2. ( a ) *Identity.* The color additive Ext. D&C Violet No. 2 is principally the monosodium salt of 2-[(9,10-dihydro-4-hydroxy -9,10-dioxo-1-anthracenyl) amino]-5-methyl-benzenesulfonic acid.
( b ) *Specifications.* Ext. D&C Violet No. 2 shall conform to the following specifications and shall be free from impurities, other than those named, to the extent that such other impurities may be avoided by good manufacturing practice: Sum of volatile matter (at 135 °C) and chlorides and sulfates (calculated as sodium salts), not more than 18 percent. Water-insoluble matter, not more than 0.4 percent. 1-Hydroxy-9,10-anthracenedione, not more than 0.2 percent. 1,4-Dihydroxy-9,10-anthracenedione, not more than 0.2 percent. *p-* Toluidine, not more than 0.1 percent. *p-* Toluidine sulfonic acids, sodium salts, not more than 0.2 percent. Subsidiary colors, not more than 1 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 80 percent.
( c ) *Uses and restrictions.* The color additive Ext. D&C Violet No. 2 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of Ext. D&C Violet No. 2 shall be certified in accordance with regulations in part 80 of this chapter.
§ 556.630 Sulfachlorpyridazine. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for sulfachlorpyridazine are: ( 1 ) *Cattle and swine.* Edible tissues (excluding milk): 0.1 ppm.
( 2 ) [Reserved]
( c ) *Related conditions of use.* See §§ 520.2200 and 522.2200 of this chapter.
Clean Air Pierce County

http://www.cleanairpiercecounty.org/[11/26/2012 12:38:35 PM]

Sign Up For Updates

Pierce County's Air

Quality

Fine particle pollution and

why it's a problem

Clean Air Task Force

Locally-recommended

actions to reduce pollution

Resource Library

Reports, videos and

weblinks

Public Input

Feedback received to

date

FAQs

Common questions about

wood smoke, burn bans

and nonattainment

Contact Us

Provide feedback or

request information

Burn Ban Status

Featured video

Pierce County TV News --

Feb 9, 2012 -- Burn Bans

More>

Pierce County has an

air pollution problem

In 2009, most of Pierce County was designated a "nonattainment

area" for fine particle pollution (soot). This means that fine particle

pollution levels too frequently exceeded the national limit, posing

public health risks.

Solving the problem takes the whole community. Check in with us

often to learn more – and participate. With your help, we'll enjoy

clean, healthy air together.

Clean Air Task Force Releases

Recommendations

Fine particles are tiny pieces of pollution. When

inhaled, these tiny particles travel deeply into

your lungs and even into your bloodstream

where they can trigger health problems. More»

Public Input

The Clean Air Task Force received feedback

from over 600 people on their draft pollutionreducing strategies. More»

What's the problem?

Simply put, ‘nonattainment' means that air

quality in Tacoma and most of Pierce County

does not meet (or attain) federal health

standards. More»

In the wintertime, you may be

breathing unhealthy levels of

fine particle pollution. Do your

part to help clear the air: 

Don't burn during a Burn Ban — it's

the law.

Consider cleaner ways to heat.

Use only dry wood that has been

split and stacked for one year.

Consider recycling or replacing your

old wood stove or fireplace insert.

New program begins Nov. 2012.

Connect with us, stay informed.

STAGE 1 BURN BAN IN 
Clean Air Pierce County

http://www.cleanairpiercecounty.org/[11/26/2012 12:38:35 PM]

About | Contact | Privacy & Terms of Use

© 2011 Puget Sound Clean Air Agency. All rights reserved.

More

Sharing

Services

Share

 

.
---

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO
  18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO 
  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of IAS COMMUNICATIONS, Inc.
  (the "Company") on Form 10-KSB for the period ending April 30, 2006 as filed
  with the Securities and Exchange Commission on the date hereof (the "Report"),
  I, John G. Robertson, President of the Company, certify, pursuant to 18 U.S.C.
  ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002,
  that:

|1. | I have reviewed the Report;                                                                                                                                                                                                                                                                                                                 
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                                                                                                                                                                                             
|2. | based on my knowledge, the Report does not contain any
        untrue statement of a material fact or omit to state a material fact necessary
        to make the statements made, in light of the circumstances under which
        such statements were made, not misleading with respect to the period covered
        by the Report; and
|   |                                                                                                                                                                                                                                                                                                                                             
|3. | based on my knowledge, the financial statements, and
        other financial information included in the Report, fairly present in
        all material respects the financial condition, results of operations,
        and cash flows of the registrant as of, and for, the periods presented
        in the Report.                      

August 14, 2006

/s/ John G. RobertsonJohn G. Robertson, President 
  (Principal Executive Officer)

---
* Pursuant to 5 TH C IR
. R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR
. R. 47.5.4. 

### IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 07-50938 Conference Calendar

UNITED STATES OF AMERICA Plaintiff-Appellee
v. WALTER VINICIO CORONADO-MAJANO Defendant-Appellant Appeal from the United States District Court for the Western District of Texas USDC No. 2:07-CR-47-ALL Before KING, STEWART, and PRADO, Circuit Judges. PER CURIAM: * Appeali ng the Judgment in a Criminal Case, Walter Vinicio CoronadoMajano raises arguments that are foreclosed by Almendarez-Torres v. United States, 523 U.S. 224, 235 (1998), which held that 8 U.S.C. § 1326(b)(2) is a penalty provision and not a separate criminal offense. U nited States v. PinedaArrellano, 492 F.3d 624, 625 (5th Cir. 2007), cert. denied, 128 S. Ct. 872 (2008). United States Court of Appeals

Fifth Circuit 

### F I L E D March 5, 2008 Charles R. Fulbruge III ClerkNo. 07-50938

2 The Government’s motion for summary affirmance is GRANTED, and the judgment of the district court is AFFIRMED.
§ 822.22 What recourse do I have if I do not agree with your decision? ( a ) If you disagree with us about the content of your plan or if we disapprove your plan, or if you believe there is a less burdensome approach that will answer the surveillance question, you may request review of our decision by: ( 1 ) Requesting a meeting with the individual who issued the order for postmarket surveillance;
( 2 ) Seeking internal review of the order under § 10.75 of this chapter;
( 3 ) Requesting an informal hearing under part 16 of this chapter; or
( 4 ) Requesting review by the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee.
( b ) You may obtain guidance documents that discuss these mechanisms from the Center for Devices and Radiological Health's (CDRH's) Web site.
[67 FR 38887, June 6, 2002, as amended at 72 FR 17400, Apr. 9, 2007; 85 FR 18443, Apr. 2, 2020]
#### § 830.210 Eligibility for use of FDA as an issuing agency.

When FDA acts as an issuing agency, any labeler will be permitted to use FDA's unique device identification system, regardless of whether the labeler is considered a small business.
* Local Rule 47.5 provides: "The publication of opinions

that have no precedential value and merely decide particular

cases on the basis of well-settled principles of law imposes

needless expense on the public and burdens on the legal

profession." Pursuant to that Rule, the court has determined

that this opinion should not be published.

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

__________________

No. 95-40057

Summary Calendar

__________________

UNITED STATES OF AMERICA,

 Plaintiff-Appellee,

versus

EVELINA FLORES,

 Defendant-Appellee.

- - - - - - - - - -

Appeal from the United States District Court

for the Southern District of Texas

USDC No. C:94-CR-144

- - - - - - - - - -

November 9, 1995

Before WIENER, PARKER and DENNIS, Circuit Judges.

PER CURIAM:*

Evalina Flores appeals her guilty plea conviction and

sentence for money laundering with the intent to promote the

delivery and sale of a controlled substance. Flores argues that

the district court erred by increasing her offense level by three

levels pursuant to U.S.S.G. § 2S1.1(b)(1). We have reviewed the

record and have determined that the district court did not commit

plain error by increasing Flores's offense level. See United

States v. Calverley, 37 F.3d 160, 162-64 (5th Cir. 1994) (en

banc).

AFFIRMED.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1460 Leucine aminopeptidase test system. ( a ) *Identification.* A leucine aminopeptidase test system is a device intended to measure the activity of the enzyme leucine amino-peptidase in serum, plasma, and urine. Leucine aminopeptidase measurements are used in the diagnosis and treatment of liver diseases such as viral hepatitis and obstructive jaundice.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2307, Jan. 14, 2000]
Fourth Court of Appeals

San Antonio, Texas

December 23, 2019

No. 04-19-00796-CV

Jane G. GARCIA,

Appellant

v.

Daniel Muniz GARCIA,

Appellee

From the County Court at Law No 2, Webb County, Texas

Trial Court No. 2017FLB001496-C3

Honorable Victor Villarreal, Judge Presiding

O R D E R

On November 12, 2019, appellant filed her notice of appeal and motion for extension of 

time to file her notice of appeal. She also filed her Notice of Filing of Declaration of Indigency 

and attached supporting documentation. The clerk’s record was then filed on December 19, 

2019. The clerk’s record reflects that (1) the trial court signed the final decree of divorce on 

August 13, 2019; (2) appellant timely filed a motion to modify the trial court’s judgment and/or a 

motion for new trial on September 10, 2019; and (3) appellant filed her notice of appeal and 

motion for extension of time to file her notice of appeal on November 12, 2019. We GRANT her 

motion for extension of time to file her notice of appeal. We further GRANT her request to 

proceed without payment of costs pursuant to Texas Rule of Appellate Procedure 20.1. See TEX.

R. APP. P. 20.1.

_________________________________

Liza A. Rodriguez, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 23rd day of December, 2019.

___________________________________

MICHAEL A. CRUZ,

Clerk of Court
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.35 Astaxanthin. ( a ) *Identity.* ( 1 ) The color additive astaxanthin is 3, 3′-dihydroxy-β, β-carotene-4, 4′-dione.
( 2 ) Astaxanthin may be added to the fish feed only as a component of a stabilized color additive mixture. Color additive mixtures for fish feed use made with astaxanthin may contain only those diluents that are suitable and are listed in this subpart as safe for use in color additive mixtures for coloring foods.
( b ) *Specifications.* Astaxanthin shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: Physical state, solid. 0.05 percent solution in chloroform, complete and clear. Absorption maximum wavelength 484-493 nanometers (in chloroform). Residue on ignition, not more than 0.1 percent. Total carotenoids other than astaxanthin, not more than 4 percent. Lead, not more than 5 parts per million. Arsenic, not more than 2 parts per million. Mercury, not more than 1 part per million. Heavy metals, not more than 10 parts per million. Assay, minimum 96 percent.
( c ) *Uses and restrictions.* Astaxanthin may be safely used in the feed of salmonid fish in accordance with the following prescribed conditions: ( 1 ) The color additive is used to enhance the pink to orange-red color of the flesh of salmonid fish.
( 2 ) The quantity of color additive in feed is such that the color additive shall not exceed 80 milligrams per kilogram (72 grams per ton) of finished feed.
( d ) *Labeling requirements.* ( 1 ) The labeling of the color additive and any premixes prepared therefrom shall bear expiration dates for the sealed and open container (established through generally accepted stability testing methods), other information required by § 70.25 of this chapter, and adequate directions to prepare a final product complying with the limitations prescribed in paragraph (c) of this section.
( 2 ) The presence of the color additive in finished fish feed prepared according to paragraph (c) of this section shall be declared in accordance with § 501.4 of this chapter.
( 3 ) The presence of the color additive in salmonid fish that have been fed feeds containing astaxanthin shall be declared in accordance with §§ 101.22(k)(2) and 101.100(a)(2) of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[60 FR 18738, Apr. 13, 1995]
Exhibit
32.1

















CERTIFICATION
PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002














In
connection with the Annual Report of Wayside Technology Group, Inc. (the
“Company”) on Form 10-K for the period ending December 31, 2009 as filed with
the Securities and Exchange Commission on the date hereof (the “Report”), I,
Simon F. Nynens, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to
§906 of the Sarbanes-Oxley Act of 2002, that:








(1)
            The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and





(2)
            The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.














/s/ Simon F. Nynens


Simon F.
Nynens


President
and Chief Executive Officer


February
22, 2010





A
signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by Company and furnished to the
Securities and Exchange Commission or its staff upon request.
§ 520.1200 Ivermectin, fenbendazole, and praziquantel tablets. ( a ) *Specifications.* Each chewable tablet contains either: ( 1 ) 68 micrograms (μg) ivermectin, 1.134 grams fenbendazole, and 57 milligrams (mg) praziquantel; or
( 2 ) 27 μg ivermectin, 454 mg fenbendazole, and 23 mg praziquantel.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* Administer tablets to provide 6 μg per kilogram (/kg) ivermectin, 100 mg/kg fenbendazole, and 5 mg/kg praziquantel.
( 2 ) *Indications for use.* For the treatment and control of adult *Toxocara canis* (roundworm), *Ancylostoma caninum* (hookworm), *Trichuris vulpis* (whipworm), and *Dipylidium caninum* (tapeworm), and for the prevention of heartworm disease caused by *Dirofilaria immitis* in adult dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[73 FR 33692, June 13, 2008, as amended at 74 FR 61516, Nov. 25, 2009]